Peptide
CJC-1295 W/IPAMORELIN NO DAC
CJC-1295 with Ipamorelin (No DAC) is a dual-peptide research blend combining a modified GHRH analogue with a selective GHS-R1a agonist, targeting two distinct points in the somatotropic axis. This is one of the most frequently investigated GH pathway blends in research settings.
The No DAC formulation provides a shorter half-life profile for research designs requiring pulsatile release modeling. Their combined use is studied for potential synergistic effects on GH pulse amplitude and frequency.
Research Applications
- Dual-pathway GH secretion research (GHRH + GHS receptor)
- Pulsatile GH release amplitude and frequency studies
- IGF-1 axis regulation and downstream signaling research
- Body composition and lean mass metabolism models
- Recovery and regenerative biology preclinical study designs
Key Features
- Dual-compound GH pathway blend — No DAC formulation
- Targets GHRH receptor and GHS-R1a simultaneously
- Research-grade purity, independently verified
- For laboratory and investigational use only
Research application details for CJC-1295 W/IPAMORELIN NO DAC. For specific protocol information, please refer to current peer-reviewed literature.
- Research-grade purity, independently verified
- Certificate of Analysis included with every order
- CJC-1295 W/IPAMORELIN NO DAC — Default Title
- Intended strictly for laboratory and research use only
This product is intended for laboratory research purposes only. This product is not approved by the FDA for human consumption, diagnosis, treatment, cure, or prevention of any disease. Not for medical or veterinary use.